#blood cancer approved drugs

[afeelgoodblog]

The Best News of Last Week - October 30, 2023

1. Bill to Ban Hidden Fees in California Signed into Law

California Attorney General Rob Bonta has released a statement regarding the signing of Senate Bill 478 (SB 478). SB 478, coauthored by Senators Bill Dodd and Nancy Skinner, will eliminate hidden fees, also known as 'junk fees,' in California starting from July 1, 2024. Hidden fees are deceptive charges that sellers include in transactions, either through obscured disclosures or later revelations, impacting consumers negatively.

2. New Portable Water Treatment System Vaporizes 99% of ‘Forever Chemicals’

A startup based Washington has devised a portable system capable of removing the vast majority of per- and polyfluoroalkyl substances, or PFAS, from water.

The system uses hydrothermal alkaline treatment, or HALT, to eliminate 99% of forever chemicals from water.

3. Tumor-destroying sound waves receive FDA approval for liver treatment in humans

The U.S. Food and Drug Administration has approved the use of sound waves to break down tumors—a technique called histotripsy—in humans for liver treatment. Technique developed at the University of Michigan provides a noninvasive alternative to surgery, chemotherapy and radiation treatments for cancer

4. Japan's top court says trans sterilisation requirement unconstitutional

Japan's Supreme Court has ruled that it is unconstitutional to require citizens to be sterilised before they can officially change genders.

The 2004 law said people could only change their gender if they have no reproductive capacity. Wednesday's ruling came after a transgender woman filed a petition challenging the law.

5. Abandoned golf courses are being reclaimed by nature

Golf courses, despite occupying large green spaces, are not necessarily good for the environment.

Conservation nonprofits and local authorities are looking to acquire golf courses that have been abandoned due to high maintenance costs, low player numbers or other reasons, and repurpose them into landscapes that boost biodiversity and build natural defenses against climate change.

6. NSW court allows health officials to give blood transfusion to Jehovah's Witness toddler

Regional New South Wales health officials have won a court order authorising them to give a blood transfusion to a Jehovah's Witness toddler if needed in surgery. The Supreme Court has been told the girl, three, who can only be referred to as JI, is in need of two surgical procedures. 

On such an application, the overriding criterion to be applied by the court is the best interests and welfare of the child.

7. North Atlantic right whale population has steadied, scientists say

The population of critically endangered North Atlantic right whales appears to have levelled off after a decade of steep decline, according to updated data released this morning by Canadian and American scientists. Scientists in the consortium said Monday that the 2021 estimate of 340 North Atlantic right whales in existence has been recalculated to 365 primarily because of the number of calves born that year.

The estimate for 2022 is 356.

---

That's it for this week :)

This newsletter will always be free. If you liked this post you can support me with a small kofi donation here:

Buy me a coffee ❤️

Also don’t forget to reblog this post with your friends.

[macgyvermedical]

Hey babe, wanna hear something hot? *whispers* history of metformin

Ok okay I'll talk

So metformin is commonly thought of as the most boring of diabetes drugs. Like, everyone who has ever thought about maybe having type 2 diabetes is taking it unless it gives them diarrhea, and even then their doctor still probably wants them to take it. But it's a first line because it's old, it's cheap, it doesn't often cause hypoglycemia, and it has relatively few side effects compared to other diabetes drugs. Also, like a lot of older drugs, it does way more than it says on the packaging. And a lot of stuff we're still learning about.

In order to talk about metformin, we have to talk about a plant called goat's rue. Goat's rue is a plant native to Europe, Africa, and Asia, and currently grows just about everywhere. In ancient times it was used as an anti-parasitic, a plague remedy, and to relieve the excessive urination caused by what might have been diabetes. In 1918 it was found to contain a chemical called galegine, which did lower blood sugar. Galegine as an anti-diabetes medication is probably too toxic to use long term. However, with a few chemical tweaks, it could become a drug that lowered blood sugar without the toxic effects. Metformin was born.

Metformin came out in 1923 and is a type of drug called a biguanide. it's actually the only type in it's class still available as an anti-diabetic agent, because the other drugs in it's class that came out in the 1920s and 30s caused lactic acidosis and liver problems (similar to the types of reactions seen with galegine), and were taken off the market.

Metformin (and pretty much all oral antidiabetic agents in development at this time) didn't do well initially, probably because they came out the same decade as insulin, and insulin was a lot more effective at treating any kind of diabetes.

It fell out of use extremely quickly, and didn't get picked up again until the 1940s, when US access to antimalarial drugs was cut off, just as a war in the pacific was ramping up. Metformin was evaluated as an antimalarial during WWII, and while noted to have some anti-malarial properties (particularly as a malaria preventative) it also was noted to significantly lower blood sugar in diabetic patients- while not lowering blood sugar very much at all in non-diabetic patients.

This effect, rather than it's antimalarial properties, was what got scientists really interested. Unfortunately, it would not be until 1957 in France that metformin had its first major studies to determine that it did, indeed, work against diabetes. Metformin lost the race to the "first" (successful) oral antidiabetic agent by a year, to a different drug that was found while looking for a new antibiotic- Diabenese.

Metformin became a commercial success in France, while Diabenese became successful in the United States. Metformin would actually not be approved for use in the US until 1995.

But now we get to talk about what metformin does and why it's so freaking cool.

Type 2 Diabetes- lowers A1C (a measure of blood sugar control) by 1-2 full points

Prevents/reverses weight gain due to antipsychotics

Prevents and treats malaria

Makes the flu shot work better

Decreases severity of respiratory illness and complications related to the flu

Changes gut microbiome for the better

Regulates periods and reduces other symptoms in people with PCOS

Lowers risk of breast, colon, and prostate cancer

Lowers risk of dementia

Lowers risk of stroke

May increase lifespan

[mindblowingscience]

The Janus kinase 2 (JAK2) protein mediates signaling from several cytokine receptors in the regulation of hematopoiesis and immune responses. Somatic mutations in human JAK2 lead to constitutive activation and cytokine-independent signaling and underlie several hematological malignancies from myeloproliferative neoplasms (MPN) to acute leukemia and lymphomas. JAK2 contains an active kinase domain and an inactive pseudokinase domain. Interestingly, pathogenic mutations mainly occur in the regulatory pseudokinase domain. Due to its critical pathogenic role, JAK2 has become an important therapeutic target. The four currently approved JAK2 inhibitors relieve symptoms but do not heal the patient or affect survival. These drugs target the highly conserved kinase domain and affect both normal and mutated JAK2 and, due to side effects, carry a black box warning that limits their use in elderly, cardiac and cancer patients. The selective inhibition of pathogenic JAK2 is a key pending goal in drug discovery that requires a precise mechanistic understanding of the regulation of JAK2 activation.

Continue Reading.

[thetepes]

Thalidomide baby: Referencing children born with birth defects caused by the use of a drug called Thalidomide, sold under the brand names Contergan and Thalomid among others, a medication that was prescribed to pregnant women in the 1950s and 1960s.

Thalidomide was promoted for anxiety, trouble sleeping, "tension", and morning sickness. While it was initially thought to be safe in pregnancy, concerns regarding birth defects arose, resulting in its removal from the market in Europe in 1961. Common side effects include sleepiness, rash, and dizziness. Severe side effects include tumor lysis syndrome, blood clots, and peripheral neuropathy. Thalidomide is a known human teratogen and carries an extremely high risk of severe, life-threatening birth defects if administered during pregnancy. It causes skeletal deformities such as amelia (absence of legs and/or arms), absence of bones, and phocomelia (malformation of the limbs). A single dose of thalidomide, regardless of dosage, is enough to cause teratogenic effects. 

The total number of infants severely harmed by thalidomide use during pregnancy is estimated at over 10,000, possibly 20,000, of whom about 40% died around the time of birth. Those who survived had limb, eye, urinary tract, and heart problems. The birth defects caused by thalidomide led to the development of greater drug regulation and monitoring in many countries.

It was approved in the United States in 1998 for use as a treatment for cancer.

[dzthenerd490]

File: The Boys - Compound V

SCP#: AHR

Code Name: The Super Drug

Object Class: Keter

Universe of Origin: Υ-17: "Broken Masquerade"

Special Containment Procedures: Samples of SCP-AHR are contained at Site-AD and stored in the Level 5 area of the biohazard Labs. Any sort of experimentation must be done in the newly constructed Modified Cavafy Reality Concealment Testing Facility of Site-AD as past testing has shown it to be the only area to withstand the unpredictability of SCP-AHR. Testing must be approved by at least five Level 4 Foundation staff members or by the Site Director Dr. Wicked. At the end of testing all subjects must be terminated and their DNA collected to be placed into the local Zartion Hominid Replicator to allow future testing with minimal hazard. 

In the event of a containment breach the entirety of the Facility is to be put on lock down and Mobile Task Force Epsilon-11 “Nine-Tailed Fox” and Mobile Task Force Hera-5 “Watch Dogs” are to be deployed immediately. 

Hosts of SCP-AHR out in the wild are to be observed by the MTF Command through Foundation satellites and hacked surveillance. They are to be reported on any potential source of blackmail or any other weaknesses that the Foundation can exploit. Once this is done, they are to be led to an area where they can be easily ambushed. Mobile Task Force Dionysus-10 “Hero Killers” is entrusted to use the exploitable weaknesses of the SCP-AHR host to contain or neutralize them easily. 

Description: SCP-AHR is a strange drug created by Group of Interest: Vought International meant to be their main and most valuable product. When SCP-AHR is injected into a living being it will target their DNA and increase a certain aspect by rewriting their entire DNA. This process is rather painful especially towards an individual who is 5 years or older with those of even older age getting the worst results. However, when someone who is 4 years or younger, or preferably a newborn they will not experience such pain but instead become more easily infused SCP-AHR. It is believed the reason for this is because a younger child or baby is obviously still developing and thus once the SCP-AHR has altered their DNA their body can grow up to better adapt to said alterations. Though said alterations are not always common for human DNA so it might not always lead to something the body can handle regardless. 

SCP-AHR alters the DNA by granting the host the ability to enhance certain aspects of themselves; for example, it can increase their speed, their strength, their intelligence, as well as their durability, most of these aspects are universal to all those who take SCP-AHR but can differ to various degrees. However, SCP-AHR can also grant the biology of the host new abilities that would otherwise be impossible to the human body. Such abilities include the ability to stretch the body, turn skin into steel on command, fly, talk to animals, create fire or other elements from the hands, and much more. 

Despite its seemingly beneficial properties, SCP-AHR has no limits in what it can grant nor what it can increase. For example, SCP-AHR can increase the chances someone gets cancer, increases your body size without granting direct control to the host, causes someone to phase through matter without ever becoming solid again, and much more terrible effects. The effects get worse when someone already has a horrible effect such as a fatal disease or worse. For example, someone who has cancer will have that cancer turn into a parasitic monster. Someone with blood disease can have their blood mutate in horrific ways. Then there's someone with a memory disorder will gain some kind of teleportation or phasing ability that makes them go on insanity rampages; killing hundreds without knowing what they are doing. 

Despite these terrible effects Vought International has not concerned itself very much with making altered versions of SCP-AHR in order to minimize the effects. The best they decided to create was SCP-AHR-24. SCP-AHR-24, or Temp V as it is called by the Company, is a military drug created to give soldiers powers for 24 hours and afterwards they will be normal again with no lasting effects. However, this was only the promise as SCP-AHR-24 actually gives the host brain cancer and a quick but painful death if they take 3 or more dosages; furthermore, there have been reports of hosts becoming heavily mutated as well. In other words, the only time Vought International decided to be somewhat responsible, they only made a worse drug. 

SCP-AHR was discovered in 1945 after World War 2 had ended, thought it was created much earlier. Frederick Vought or as he was known [Data Expunged] when he was working for Obskurakorps was experimenting with the first version of SCP-AHR on Jewish prisoners provided by the rest of the Nazi party. However, near the end of the war after Hydra revealed itself and declared independence away from the rest of the Nazi party as well as the rise of PENTAGRAM with its star defender Captain America, he knew it was time for a change. Frederick Vought escaped to america and changed his name but revealed SCP-AHR to PENTAGRAM in exchange for a pardon of all his crimes by the president. The president agreed and soon after the Foundation found out leading them to injecting him with [data expunged] killing him in the same year of 1945. Though to the public he appeared to have died due to natural causes. 

Now pardoned Fredrick Vought created SCP-AHR and had volunteer subjects injected to create a whole batch of super soldiers. The one who stood above them all was Soldier Boy who was advertised to be even better than Captain America in every way. Unfortunately, due to Captain America disappearing and Soldier Boy still being alive and well he was viewed as better by the public and thus was recognized as a real American hero while Captain America was often seen as a failure. Due to the Foundation and the rest of the ACPA being forced to cover up all information about the Red Skull and the rest of Hydra the world never knew of Captain America’s real heroism, nor did they know that Soldier Boy never actually did anything. He only just showed up in movies and commercials to advertise the war while Captain America did the real work. 

This trend only empowered the newly formed Vought International to continue this ploy of granting regular people SCP-AHR and giving those who had the best powers to be recognized as heroes. Though in reality they were celebrities that only advertised for Vought International and participated in staged criminal acts to obtain fame and glory all for the sake of more money, drugs, and prostitutes. It is for this reason and the fact that Vought International is one of the main reasons that the veil of Secrecy was broken in the first place is why they are viewed with hostility by the Foundation. It is with hope that Foundation experimentation and testing will allow us to find a way to combat SCP-AHR without major repercussions. 

Update - 2015 - The Foundation has created SCP-AHR-Null which is a drug that neutralizes the anomalous abilities of those infected with SCP-AHR. This is planned to be merely the first step in eradicating Vought International's power and crushing the company for good. There is still the fact that they are heavily protected by the insurance of Goldbaker-Reinz Ltd. The Foundation cannot afford to stand against Goldbaker-Reinz Ltd or at least not do so without heavy consequences.

.

SCP: Horror Movie Files Hub

[wickedsrest-rp]

Name: Katherine “Kit” Clarke Species: Vampire (previously spawn vampire) Occupation: Unemployed Age: 74 Years Old (Looks about 36) Played By: Chayya Face Claim: Ruth Negga

"A little party never killed nobody… Oh, wait. Never mind."

TW: Terminal illness (breast cancer), drug abuse

Don’t believe the tabloids, okay, Kit Clarke grew up in a perfectly normal household just south of Hoboken, New Jersey. Just them and their mom and their dad and the both of them were doctors, if you can believe it. Brain-numbingly normal. They wanted the best for Kit and were often able to provide. When they started to show a real aptitude and love for music, they took that into account with piano lessons, voice training, and a gorgeous acoustic guitar. Overall, the Clarke household was loving, if ambitious, and as long as they got good grades, Kit was able to pursue their own interests as well. 

But they were, still, eventually, a teenager, and one with a fun-seeking edge. Growing up where they did, it wasn’t hard at all to sneak into the City. It was innocent, for the most part – exploring the city, watching the people and, of course, checking out the music venues. Any club that would let a kid so obviously underage come in was on Kit’s radar and they become a regular. And when they had open mics, well, how could they resist?

And that’s how Kit met Matty. He heard them sing in some crappy, hole-in-the-wall club that he had snuck out to and the rest is history. Or, at least, the rest is better left to be hashed out by VH1’s Behind the Music and MTV’s Where Are They Now?

Matty and Kit ran deep, quickly, and it wasn’t long before they were putting together a band. It was just smashing around, in those early days, just jamming and giggling and making dreamy-eyed plans. Kit’s parents Did Not Approve, but, hey, they were still keeping their grades up so they let it go. But then Kit told them that they were skipping out on college, that the band had actually landed some gigs and they wanted to make a real go of it. They may have had dreams of them becoming a doctor, like them, or something else stable and steady and normal, but Kit was eighteen by then and they done this to themselves in some sense. They raised Kit to be independent and ambitious and unapologetic and that’s how they ran off with the band. 

And god, it was good. It was amazing. It was more than Kit ever could have imagined, traveling the country with this band that was easily becoming a second family. Making music and playing it and having people like it. Insane. And they got to do it all with their best friend. It was cosmic shit, what they were doing and  they loved every second it (except maybe the fucking tabloids but, well, every rose, right?). It was a whirlwind boardwalk ride and through it all Kit wrote letters to their parents, sent them money even though they didn’t need it. They wrote back asking if they were okay, asking when they would be coming home next, tentatively trying to address the rumors they had read about drugs in the band.

And then Matty was turned and that sure was a trip. Kit was the one who found him, crazed and bloody and with no heartbeat in some alleyway. But just like everything else, they figured it out, together, as a band, as a family. And it turned out they all rocked through it. Diamondbacks charged on. And now they had proof they could outlast anything. 

Until Kit’s diagnosis came in.

It was triple-negative and it had spread and they could try chemotherapy but their odds weren’t good. And then they tried the chemotherapy and it was awful, they’ve never felt so sick. They stopped the treatment, wanting to go home and die in peace. Except that wasn’t the plan at all because they had, shamefully, asked Matty to turn them and he agreed. Only it all went wrong.

Forty years of nothing. Forty years of just blood and cravings and hunger and instinct and hunting. Forty years of feed, feed, feed, with only the barest brush of comfort from Matty at the edges of their consciousness, in their bond.

Coming back was excruciating. Regaining their mind, regaining control and full consciousness. It all hurts and it’s all hard, even with Matty by their side.

Character Facts:

Personality: Fun-loving, friendly, compassionate, goofy, musical, ambitious, tempestuous, avoidant, wary

Happily responds to any pronouns but prefers “they” and “she.”

A founding member of The Diamondbacks with Matty, Kit was one of the key lyricists and bassists and would often lend a hand on vocals. They can also play guitar and keyboard well, but their instrumental prowess is nowhere near Matty’s virtuoso talent. 

To the rest of the world, Kit died in 1983 from breast cancer. Only those in the band know what truly happened.

Yes, they still talk with a North Jersey accent, whadda ya gonna do aboudit?

They’ve technically not been around for the past 40 years or so there’s a lot for them to adjust to and learn. No one tell them about that other guy who’s singing in Van Halen.

[spiritualdirections]

"For the first time, an oral contraceptive is going to be available over the counter, without a prescription. On July 13, the Food and Drug Administration (FDA) announced that it has approved the contraceptive pill Opill. Many are praising the FDA’s decision as a significant step toward making contraception more widely available. Perrigo Company, the pill's Dublin-based manufacturer, stated that Opill will most likely be available in grocery and convenience stores, as well as online, in early 2024. Perrigo’s president and CEO Murray Kessler called the FDA’s decision “a new, groundbreaking chapter in reproductive health.”  "It may indeed be groundbreaking—but not for the reason Kessler believes. Contrary to popular myth, increased use of contraception is correlated to an increase in abortions. And despite what proponents claim, hormonal birth control has a damaging effect on both mental and physical health...Opill, like other forms of hormonal birth control, primarily consists of progestin, “a hormone that thickens mucus in the cervix to make it harder for sperm to enter the uterus,” according to the New York Times. Opill is said to be less effective than pills with both progestin and estrogen, yet defenders of the FDA’s decision say that Opill is still highly effective as long as it is taken at the same time every day."

The article makes the point, which everyone who studies this knows, that the pill actually increases nonmarital pregnancies, because the pill requires regular use, and the kind of people who are not disciplined enough to wait until marriage are often also not disciplined enough to take a pill every day. This version of the pill seems to require an extraordinary high level of discipline--it must be taken at the same time every day. "Unintended" pregnancies in the U.S. basically never occur because contraceptives aren't available, but because the couple does not use them properly.

The article also makes the point about the extensively documented link between the pill and depression, which I've blogged about before. It might have mentioned the link between the pill and blood clotting, which might be dangerous if the pill is taken over the counter and the user is not in touch with a doctor.

The article does not make a point that it easily could have, that this is a huge win for Big Pharma. Notice that it is the CEO who calls this "groundbreaking." I'm assuming the Biden administration will get its fair share of donations this cycle.

The article also does not discuss something that I think is relevant. Typical birth control pills are on the list of known carcinogens by the International Agency for Research for Canger (IARC), a project of the World Health Organization. They are in category 1, the same as tobacco. It's likely that the explosion in cases of breast cancer over the last 50 years is caused by increasingly widespread use of the hormones in the pill. The CDC says that using the pill increases a woman's chances of breast and cervical cancers by as much as 60%. As I wrote a few years ago, "It’s safer to smoke 5-8 cigars daily (relative risk of cancer 1.17; see Table 3)–which almost nobody does–than to be on the Pill (relative risk 1.24 for current users)." 

(The article does not say more about whether the reduced amount of estrogen is intended to make Opill less carcinogenic, but I can't imagine that we have sufficient data on this particular pill to determine this.)

The argument for having restrictions on tobacco sales is that tobacco causes cancer. The same argument should argue for at least the same restrictions on Opill. Defenders of the pill will point to studies that show the likelihood of cancer drops off once someone stops using the pill (as in the CDC link above); the likelihood of cancer also drops off once someone quits smoking cigarettes. Given these parallels, I would think that states would want to pass laws restricting over the counter sales of either carcinogen to minors.

The more people become aware that playing with the hormones in the body is not that safe, the more people will switch to using fertility awareness methods, which are natural and more in tune with the environment. But these natural methods don't make Big Pharma any money!

[particularj]

This is huge.

Biden is directing the power of HHS and Medicare / Medicaid’s purchasing & approval power to force drug makers to negotiate lower prices or risk steep penalties. And they (begrudgingly and after filing lawsuits) agreed to negotiate!

Why? The penalty if they didn’t, they’d have to pay 65-95% taxes on drug sales or withdraw ALL of their companies’ drugs from the formulary.

The government is pushing to cut prices 25% by 2026, which would save billions annually.

The first round includes 10 high-demand, brand name drugs without generics despite years of being on the market, and for conditions such as high blood pressure, diabetes, and cancer. In other words, these are life-saving drugs.

By pushing price cuts, it can show how drug manufacturers CAN lower prices across the market, because they are making money hand over fist.

The irony? A drug manufacturer spokesperson indicated this ‘choice’ to negotiate wasn’t a fair or real choice. Oh? Like the choice between buying your blood pressure medication or your diabetes medication, because of how much y’all charge? Or maybe between all of their meds and their heat? Hmm?

Get fucked drug makers. You have blood on your hands and you use the idea that you are good people making medicine for people to cover the fact you are even more greedy than the average company by profiteering on a product people literally can’t live without. Universal healthcare for all.

[spooniestrong]

Why you should avoid kava and 9 other risky dietary supplements

One-third of Americans say they believe supplements have been tested by the Food and Drug Administration for safety, according to a 2022 nationally representative survey by Consumer Reports of 3,070 adults in the United States. But the FDA doesn’t approve or test the safety or effectiveness of any supplement before it enters the U.S. market.

After consulting with a panel of doctors and researchers, Consumer Reports says you should avoid these 10 risky supplements. In general, risk increases the larger the dosage and the longer the supplement is taken. Also beware of illegal or unapproved drug ingredients, such as tianeptine, methylsynephrine and phenibut.

Chaparral

Also called: creosote bush, greasewood, Larrea divaricata, Larrea tridentata, larreastat

Claimed benefits: weight loss; eases inflammation; treats colds, infections, rashes, cancers

Potential harms: kidney problems, liver damage

Coltsfoot

Also called: coughwort, Farfarae folium leaf, foalswort, Tussilago farfara

Claimed benefits: relieves cough, sore throat, laryngitis, bronchitis, asthma

Potential harms: liver damage, possible carcinogen

Comfrey

Also called: blackwort, bruisewort, slippery root, Symphytum officinale

Claimed benefits: relieves cough, heavy menstrual periods, stomach problems, chest pain; treats cancer

Potential harms: liver damage, cancer

Germander

Also called: Teucrium chamaedrys, Teucrium viscidum

Claimed benefits: weight loss; alleviates fever, arthritis, gout, stomach problems

Potential harms: liver damage, hepatitis

Greater celandine

Also called: celandine, Chelidonium majus

Claimed benefits: alleviates stomach ache

Potential harms: liver damage

Kava

Also called: ava pepper, kava kava, Piper methysticum

Claimed benefits: eases anxiety, helps sleep

Potential harms: liver damage, exacerbates Parkinson’s disease and depression, impairs driving

Lobelia

Also called: asthma weed, Lobelia inflata, vomit wort, wild tobacco

Claimed benefits: helps respiratory problems, smoking cessation

Potential harms: nausea, vomiting, diarrhea, tremors, rapid heartbeat, confusion, seizures, hypothermia, coma

Pennyroyal oil

Also called: Hedeoma pulegioides, Mentha pulegium

Claimed benefits: improves breathing problems, digestive disorders

Potential harms: liver and kidney failure, nerve damage, convulsions

Usnic acid

Also called: beard moss, tree moss, usnea

Claimed benefits: weight loss, pain relief

Potential harms: liver injury

Yohimbe

Also called: Johimbi, Pausinystalia yohimbe, yohimbine, Corynanthe johimbi

Claimed benefits: treats low libido and erectile dysfunction, depression, obesity

Potential harms: raises blood pressure; causes rapid heart rate, headaches, seizures, liver and kidney problems, heart problems, panic attacks

Source: Consumer Reports Inc.

Consumer Reports is an independent, nonprofit organization that works side by side with consumers to create a fairer, safer, and healthier world. CR does not endorse products or services, and does not accept advertising. Read more at ConsumerReports.org.

[healthlineonline]

Get Arimidex for Sale and Control Estrogenic Side Effects

Many anabolic steroids convert androgenic properties to estrogen, which leads to severe estrogenic side effects. Steroid users control these side effects by using additional medication during or after their anabolic cycles. Anastrozol is a well-known drug that reduces estrogen levels to stop estrogenic negative impacts efficiently. This aromatase inhibitor prevents the aromatase enzymes from converting androgen into estrogen. Arimidex is a popular brand name for medicines containing Anastrozol substance. Purchase Arimidex for sale and get a wide range of benefits for bodybuilding. This non-steroidal drug prevents water retention, gynecomastia, and bloating. Arimidex helps you keep a controlled blood pressure during anabolic cycles. It is highly beneficial in slowing down the growth of tumors that feed off estrogen. Anastrozol is an FDA approved drug that treats breast cancer in postmenopausal women. Get Anastrozol from Sciroxx and use it for an advanced post-cycle therapy. It maintains an optimal testosterone level and works wonders in hormone replacement therapies.

[priteshwemarketresearch]

Lorlatinib Market Analysis: A Comprehensive Look at Non-Small Cell Lung Cancer (NSCLC) and Other Cancers

Exploring the Lorlatinib Market: Trends, Opportunities, and Future Prospects

In the dynamic world of oncology, lorlatinib has emerged as a critical therapeutic option for patients with advanced non-small cell lung cancer (NSCLC). Known for its ability to target specific genetic mutations, lorlatinib represents a significant advancement in personalized cancer treatment. This blog provides an overview of the current lorlatinib market, highlighting key trends, opportunities, and future prospects.

sample copy of this report: https://wemarketresearch.com/reports/request-free-sample-pdf/lorlatinib-market/1553

What is Lorlatinib?

Lorlatinib is a highly selective tyrosine kinase inhibitor (TKI) designed to target anaplastic lymphoma kinase (ALK) and ROS1 gene rearrangements, which are often present in NSCLC. By inhibiting these genetic drivers, lorlatinib helps to disrupt cancer cell growth and proliferation, offering hope to patients with advanced or resistant forms of the disease.

Market Trends

Growing Adoption in NSCLC Treatment: Lorlatinib has gained recognition for its efficacy in treating ALK-positive NSCLC, particularly in patients who have developed resistance to other ALK inhibitors. Its ability to penetrate the blood-brain barrier and target brain metastases has further solidified its role in managing advanced disease. As awareness and clinical experience with lorlatinib grow, its adoption in clinical practice is expected to increase.

Expanding Label and Indications: Initially approved for use in patients who have previously been treated with other ALK inhibitors, lorlatinib’s indications are expanding. Ongoing research and clinical trials are exploring its potential use in earlier lines of treatment and in combination with other therapies. This expansion could significantly enhance its market reach and applicability.

Competitive Landscape: Lorlatinib operates in a competitive market with other ALK inhibitors like crizotinib, alectinib, and brigatinib. However, lorlatinib’s unique profile—especially its effectiveness against brain metastases—provides a distinct advantage. The competitive landscape drives ongoing innovation and improvements in drug offerings, benefiting patients with more treatment options.

Opportunities in the Lorlatinib Market

Market Expansion: The global market for lorlatinib is poised for growth as more regions gain access to the drug. While it is currently approved in several countries, expanding into emerging markets presents significant opportunities. Additionally, expanding its use to different lines of treatment and combinations could further broaden its market scope.

Combination Therapies: Combining lorlatinib with other targeted therapies or immunotherapies could enhance its effectiveness and address various resistance mechanisms. Research into combination strategies is an exciting area of development, with the potential to improve patient outcomes and drive market growth.

Personalized Medicine: The rise of personalized medicine is a key driver for lorlatinib’s market potential. As more patients are identified with ALK or ROS1 mutations, the demand for targeted therapies like lorlatinib is expected to increase. Advances in genetic testing and diagnostics will likely contribute to more precise and effective treatment plans.

Challenges and Considerations

High Cost of Therapy: The cost of lorlatinib, like many targeted therapies, can be high. Ensuring affordability and access for patients is a significant challenge. While drug pricing strategies and insurance coverage play a role, ongoing efforts to address cost barriers will be crucial for broader adoption.

Resistance and Efficacy: Despite its effectiveness, some patients may develop resistance to lorlatinib over time. Continued research into mechanisms of resistance and potential solutions will be essential for maintaining its long-term utility and effectiveness in treating NSCLC.

Regulatory and Market Dynamics: Navigating regulatory approvals and market dynamics can be complex. Drug developers must manage these aspects carefully to ensure timely access and competitive positioning in the market.

Market Segments

By Distribution Channel

Hospitals

Retail Pharmacies

Online Pharmacies

Lorlatinib Industry: Regional Analysis

North America Market Forecast

With a market share of more than 47%, North America commands the largest revenue-generating portion in the lorlatinib industry. Lorlatinib acceptance is driven by high occurrences of non-small cell lung cancer (NSCLC) in North America, as well as a sophisticated healthcare system and substantial research funding. Because of the robust regulatory framework in the U.S., drugs can be approved more quickly and made widely available, which improves their market presence and patient accessibility.

Market statistics for Europe

The demand for lorlatinib is fueled in part by Europe's robust healthcare systems and high cancer rates. Nonetheless, different national healthcare laws and reimbursement procedures have an impact on market expansion. Compared to Eastern Europe, where accessibility is impacted by healthcare inequities and economic constraints, Western Europe has greater adoption rates.

Key Benefits of Lorlatinib

Targeted Therapy: Unlike traditional chemotherapy, which affects healthy cells, lorlatinib specifically attacks cancer cells with the ALK mutation.

Improved Outcomes: Clinical trials have shown that lorlatinib can significantly extend the lives of patients with ALK-positive NSCLC.

Oral Medication: The convenience of taking a pill compared to intravenous treatments enhances patient quality of life.

Future Outlook

The future of the lorlatinib market looks promising, with several factors contributing to its growth. As research advances and more indications are explored, lorlatinib is likely to play an increasingly important role in the treatment of NSCLC and potentially other cancers. Innovations in drug development, personalized medicine, and global market expansion will further shape its trajectory.

Conclusion,

lorlatinib represents a significant advancement in the management of ALK-positive NSCLC, offering hope for patients with advanced disease. The market for lorlatinib is evolving rapidly, driven by clinical advancements, competitive dynamics, and a growing focus on personalized treatment. For investors, healthcare professionals, and patients, lorlatinib stands out as a beacon of progress in the fight against cancer.

[onlymollygibson]

Im no expert but I'm a grad student working on a paper in this field.

Cancer is a bunch of diseases lumped togethet, so there will never be a one size fits all cure, just better and better treatments.

That said, the current treatments in the pipeline are incredible.

Cancer vaccines like the article talks about. Basically tumors exist because the immune system doesn't notice them as foreign or diseased, or it does notice but can't fight them because the tumor is actively suppressing the immune system. Cancer vaccines train your body's natural defenses to kill the cancer cells. Chefs kiss! Incredible science. Note that they surgically removed most of the tumor first in this trial, so it's a case of doing most of the work in surgery and letting your immune system do the cleanup.

Theyre finding in general that modern therapies like cancer vaccines or other immune boosting treatments work best in synchrony with other treatments (chemo, radiation, surgery) to get the last little bits that aren't taken out by surgery, or are resistant to chemo, etc. Immunotherapy doesn't necessarily do great at getting into tumors and wiping them out all on its own, but it's fantastic at killing the last remnants and prolonging remission or ensuring the cancer doesn't come back at all.

Some other cool immunotherapies and nanomedicines for cancer in the works (some are approved, some are still being developed.)

CAR T cells - remove white blood cells from the body, train them to attack the cancer and put them back in. Seriously look it up if you want your mind blown. This won the Nobel prize a few years back.

Nanocarriers for drugs- a big problem of cancer medicines is targeting - how do we kill the cancer while not harming the rest of the body too much. They're designing nano and micro scale encapsulation for drugs that get them to the cancer, either through direct chemical targeting or by taking advantage of the structural differences of tumors like blood vessels that are "leaky," meaning they let stuff through that non-tumor blood vessels don't. Some formulations are designed to decrease liver accumulation, or hide from the immune system. Early stages still but expect to see great things. They're trying everything from metal nanoparticles to cell membrane derived drug packaging to DNA origami. It's incredible.

Other immunotherapies: basically anything that activates the immune system to turn on the cancer. Everything from the aforementioned cancer vaccines, to cytokines (like hormones but for the immune system), to little "backpacks" made out of lipids that attach to tumor infiltrating lymphocytes (white blood cells that can get into the tumor) and deliver immune activating factors straight into the tumor by tagging along with cells that are going in anyways.

There's more but I have to analyze data now. Science is incredible!

The discovery represents a potential new way to recruit the immune system to fight treatment-resistant cancers using an iteration of mRNA technology and lipid nanoparticles, similar to COVID-19 vaccines, but with two key differences: use of a patient’s own tumor cells to create a personalized vaccine, and a newly engineered complex delivery mechanism within the vaccine.

Within 48 hours, the four human study participants showed remarkable results: their immune systems went into turbo cancer-destroying mode. And without surgery, radiation, or dangerous chemotherapy.

Folks, we may have a cure for cancer within your lifetime.

[papirouge]

I’m from the usa and since tiktok is getting banned I’ve gotten a lot of good videos from people talking why billionaires like Zuckerberg and musk act the way they do

One guy I think said it best - they are afraid of dying. Death makes them equal to the rest of us and they feel that sense of superiority over us normal people should always remain even after death when it literally won’t. Peter there spent millions on blood transfusions from younger boys so he could prolong his life because of this fear (he also admitted that one of his biggest fears is being torn apart by “the poor” and killed by us. There’s another man who’s on an extreme diet of supplements to extend his life (he broke up with his girlfriend after she got breast cancer from trying the same diet because he thought it would hurt his brand image too much)

These billionaires are trying to spend their way into immortality and out of death. When the Bible says money is the root of all evil, I think it references this as people don’t look at Gos and eternal life in heaven though Him but they see their money as the ticket to eternal life

I definitely think billionaires are soulless ghouls that'd rather waste time trying to live forever but I think you're overestimating them anon. Fear of death is not what makes Musk that lame, he's just some bored addicted to ketamine divorced man with waaaaay too much money in his hands. If he truly was afraid of death, he wouldn't be slacking his neuralink project like that. Of all his endeavors, this one is the least compelling one so far. If anything, he seems more committed to attention than immortality. Attention is what he thrives for - not really life. Dude is spending it all terminally online. He doesn't come off as someone having a fulfilling life IRL...

I don't think Elon Musk is just a piece of shit..... If anything : he is lame. That's what makes him so annoying. And a lame person with a desperate need for attention & approval, at that. Piece of shit are plenty online. But not every POS plateforms themselves for billions of people to watch AND try soooo hard being edgy and funny when dude is pushing 60. (His stunt on 4chan had to be one of the most embarrassing thing I've seen in 2024). That's why he's terminally online. His ketamine addiction would make me believe he doesn't believe half of what he says but the sleuths have found he follows actual white supremacists xitter accounts (which remove any benefit of the doubt to his infamous salute), and the Adrian Dittman stunt is way too elaborate to be only a drug fueled momentum.

I'm actually shocked that people are disappointed by Zuckerberg though. Like didn't we collectively agree he was a human lizard? Why expect anything from him? He made Facebook to hit on girls and called "fuckers" the people dumb enough to provide all their personal info online...

This "alt right"-ization of big tech has the benefit of removing any subversiveness of the right/conservative though. Now that Facebook removed fact check, enables slurs, etc. there's no more "censorship boogyman" to point fingers at. It shows that money has no color, political alignement or value. It's absolutely crazy how no one seems to remember that 2 years ago Zuck & Musk were supposed to go on a fist fight. All of this was nothing short of a mascarade. Musk and Zuck play(ed) some good cop bad cop charade - the good or bad depending on where you are on the political spectrum. Both sucks for a bunch of different reasons, but at least Zuck knows to shut the f up, but Musk doesn't, which explains why is so insufferable. I'd be surprised Musk had the longevity of Zuck bc dude has been spiralling for a hot minute, now. His falling off with Trump (because the question is not if but WHEN it will come) will be glorious lmao

[neosciencehub]

India approved a living drug to treat Blood Cancer

India approved a living drug to treat Blood Cancer @neosciencehub #India #BloodCancer #CDSCO #livingdrug #Qartemi #neosciencehub

For Indian patients with blood cancer who are at an advanced or relapsed stage of the disease, a “living drug” has been licensed. Patients with B-cell Non-Hodgkin Lymphoma (B-NHL) can now receive Qartemi, a CAR-T cell therapy, thanks to Immuneel Therapeutics, a biotech business based in Bengaluru. After the Central Drugs Standard Control Organization (CDSCO) authorized the indigenous NexCAR19,…

[global-research-report]

The Evolving Flow Cytometry Market: Key Trends and Opportunities in 2025

The global flow cytometry market size is expected to reach USD 7.01 billion by 2030, registering a CAGR of 6.96% over the forecast period, according to a new report by Grand View Research, Inc. Technological advancements in the technique are introducing new and improved analytical tools, which include the development of microfluidic flow cytometry for Point-of-Care (PoC) testing. Furthermore, the rising prevalence of cancer, immunodeficiency disorders, and infectious diseases is driving the industry. In addition, increasing R&D investments in biopharmaceutical, life science, and biotechnology research activities have led to high demand for flow cytometry instruments. In recent years, a key focus has been on the development of portable microfluidic flow cytometry devices for PoC testing.

Microfluidics and flow cytometry together make a useful tool to measure multiple characteristics of biological samples. For instance, the easy availability of several microfluidics and miniaturized detectors have enabled the creation of microchip-based cytometers, such as optofluidic cytometer, imaging cytometer, and impedance cytometer. The development of microfluidic flow cytometry devices, which are cost-effective, portable, and compact, is beneficial. They are affordable in developing economies, such as Asia & Africa, and are enabling rapid growth in PoC testing applications. Furthermore, improvements in fluorescent dyes and the increasing utility of benchtop cytometers for academic research settings are expected to drive the industry.

Developments in multicolor flow cytometry are accelerating the adoption of the technique in novel drug development activities. For instance, in January 2020, DxFLEX, CE-IVD, a 13-colour clinical flow cytometry system was launched by Beckman Coulter Life Sciences in Europe. Similarly, easy cellular analysis by simultaneous evaluation of several parameters allows extensive use of such devices for contract research purposes. The COVID-19 pandemic also spurred innovations in the technique, as evidenced by the launch of new products in this domain. For instance, in July 2021, Metropolis Healthcare Ltd. launched CoviRisk-TBNK, a simple blood test to detect the risk status of a COVID-19 hospitalized patient.

It helps analyze patients’ need for ICU facilities or ventilation and aids in the reduction of stress on healthcare resources. The test is a flow cytometry-based lymphocyte subset assay and is IVD-approved. Such innovations are anticipated to fuel industry growth in the near future. Moreover, flow cytometry is a significant tool in listing and characterizing immune cells, and is also helpful in recognizing and validating underlying genetic defects. The technique is also used to observe and monitor the immune response of patients after stem cell transplantation, and hence, organ transplantation plays an important role in boosting industry growth. According to the WHO, around 50,000 stem cell transplantations are performed globally every year, and this number is expected to grow in the near future, broadening the scope of applications for the technique.

On the other hand, instruments are highly expensive, and hence, buyers in several developing countries may not be able to afford technologically advanced flow cytometry equipment. These instruments may cost over USD 100,000 and pose significant budgetary constraints for small- & mid-sized hospitals and clinical laboratories. However, some manufacturers, such as Sony, are trying to launch newer instruments using software to automate a number of processes. Such developments would not only improve the usability of the technique but also help bring down the average instrumentation cost-under USD 100,000-in the near future.

Flow Cytometry Market Report Highlights

The instrument product segment held the largest share in 2023 due to technical advancements, as well as increased prevalence of chronic conditions

The cell-based flow cytometry technology dominated the industry in 2023 due to the high demand for early diagnosis and rising awareness about the associated benefits of cell-based assays

By application, the clinical segment accounted for the largest revenue share in 2023 owing to increased activities pertaining to infectious diseases, such as influenza, HIV, and COVID-19, among others

The academic institutes end-user segment led the market in 2023 owing to increased R&D activities by academic institutes & research centers

North America was the leading region in 2023 due to the high implementation of scientifically advanced flow cytometry solutions, high healthcare expenditure, and well-established healthcare infrastructure in the region

Asia Pacific is expected to register the fastest CAGR from 2022 to 2030 owing to the extensive growth in the pharmaceutical and biotechnology industries in emerging economies, such as China and India

Flow Cytometry Market Segmentation

Grand View Research has segmented the global flow cytometry market report based on product, technology, application, end-use, and region:

Flow Cytometry Technology Outlook (Revenue, USD Million, 2018 - 2030)

Instruments

Cell Analyzers

Cell Sorters

Reagents & Consumables

Software

Accessories

Services

Flow Cytometry Technology Outlook (Revenue, USD Million, 2018 - 2030)

Cell-based

Bead-based

Flow Cytometry Application Type Outlook (Revenue, USD Million, 2018 - 2030)

Research

PharmaceuticalApoptosis

Drug Discovery

Stem Cell

In Vitro Toxicity

Cell Sorting

Cell Cycle Analysis

Immunology

Cell Viability

Others

Industrial

Clinical

Cancer

Organ Transplantation

Immunodeficiency

Hematology

Autoimmune Disorders

Flow Cytometry End-use Outlook (Revenue, USD Million, 2018 - 2030)

Commercial Organizations

Biotechnology Companies

Pharmaceutical Companies

CROs

Hospitals

Academic Institutes

Clinical Testing Labs

Flow Cytometry Regional Outlook (Revenue, USD Million, 2018 - 2030)

North America

US

Canada

Europe

UK

Germany

France

Italy 

Spain

Denmark

Sweden

Norway

Asia Pacific

Japan

China

India

Australia

Thailand

South Korea

Singapore

Latin America

Brazil

Mexico

Argentina

Middle East & Africa

South Africa

Saudi Arabia

UAE

Kuwait

List of Key Players

Danaher

BD

Sysmex Corporation

Agilent Technologies, Inc.

Apogee Flow Systems Ltd.

Bio-Rad Laboratories, Inc.

Thermo Fisher Scientific, Inc.

Stratedigm, Inc.

Miltenyi Biotec

Cytek Biosciences

Sony Group Corporation (Sony Biotechnology Inc.)

Order a free sample PDF of the Flow Cytometry Market Intelligence Study, published by Grand View Research.

[credenceresearchdotblog]

The Leukemia Therapeutics Treatment Market is projected to grow from USD 15296.7 million in 2024 to an estimated USD 26086.71 million by 2032, with a compound annual growth rate (CAGR) of 6.9% from 2024 to 2032.Leukemia, a type of cancer affecting blood and bone marrow, remains a significant global health challenge. With increasing cases worldwide and advancements in medical research, the leukemia therapeutics treatment market is experiencing robust growth.

Browse the full report at https://www.credenceresearch.com/report/leukemia-therapeutics-treatment-market

Market Overview

Leukemia is classified into several types, including acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML). The treatment options vary by type and severity, ranging from chemotherapy and radiation therapy to targeted therapy and bone marrow transplantation.

In recent years, the market for leukemia therapeutics has expanded significantly, driven by technological advancements, increased prevalence of the disease, and rising healthcare investments. According to industry reports, the global leukemia treatment market was valued at approximately USD 12 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 7.5% through 2030.

Key Market Drivers

Rising Incidence of Leukemia:

The increasing global burden of leukemia is a primary growth driver. Factors such as aging populations, environmental exposures, and genetic predispositions contribute to the rising incidence rates.

Advancements in Precision Medicine:

Targeted therapies, such as tyrosine kinase inhibitors (TKIs) and monoclonal antibodies, have revolutionized treatment approaches. These therapies offer greater efficacy with fewer side effects compared to traditional chemotherapy.

Development of Immunotherapies:

Immunotherapies, including CAR-T cell therapy and immune checkpoint inhibitors, are at the forefront of innovation. These therapies leverage the body's immune system to fight cancer cells, offering promising outcomes for patients with advanced stages of leukemia.

Increased Funding and Research:

Governments and private entities are investing heavily in cancer research and drug development. For instance, initiatives like the Cancer Moonshot in the United States aim to accelerate the discovery of new therapies.

Favorable Regulatory Landscape:

Expedited drug approvals and orphan drug designations by regulatory bodies like the FDA and EMA encourage the development of novel leukemia treatments.

Challenges in the Market

Despite significant progress, the leukemia therapeutics market faces several challenges:

High Treatment Costs:

Advanced therapies like CAR-T can cost hundreds of thousands of dollars, making them inaccessible to many patients, especially in low- and middle-income countries.

Side Effects and Resistance:

While targeted therapies have improved outcomes, issues like drug resistance and adverse effects remain critical concerns.

Complexity of Clinical Trials:

Developing leukemia drugs often involves complex and lengthy clinical trials, delaying time-to-market for new treatments.

Disparities in Access:

Geographic and economic disparities limit access to cutting-edge treatments, with patients in developing regions particularly disadvantaged.

Emerging Trends

Gene and Cell Therapy:

Gene-editing technologies like CRISPR and advancements in cell therapy are paving the way for personalized treatments that address the genetic basis of leukemia.

Artificial Intelligence in Drug Development:

AI and machine learning are being leveraged to accelerate drug discovery, optimize clinical trial design, and identify patient-specific treatment strategies.

Combination Therapies:

Researchers are exploring the potential of combining multiple therapeutic approaches, such as targeted therapy with immunotherapy, to improve treatment outcomes.

Biosimilars:

As patents for blockbuster drugs expire, biosimilars are entering the market, offering cost-effective alternatives and increasing patient accessibility.

Future Outlook

The leukemia therapeutics treatment market is poised for transformative growth, fueled by continuous innovation and an increasing focus on precision medicine. Collaboration among pharmaceutical companies, academic institutions, and governments will be crucial in overcoming existing challenges and ensuring equitable access to life-saving treatments.

Key Player Analysis:

AbbVie (North Chicago, U.S.)

Amgen Inc. (Thousand Oaks, U.S.)

Bristol-Myers Squibb (New York, USA)

Hoffmann-La Roche (Basel, Switzerland)

Johnson & Johnson Services, Inc. (New Brunswick, U.S.)

Lupin Ltd. (India, Mumbai)

Novartis (Basel, Switzerland)

Pfizer Inc. (New York, U.S.)

Sanofi/ Genzyme Corporation (Paris, France)

Takeda Pharmaceutical Co Ltd (Tokyo, Japan)

Segmentation:

By Type of Leukemia

Acute lymphocytic leukemia (ALL)

Chronic lymphocytic leukemia (CLL)

Acute myeloid leukemia (AML)

Chronic myeloid leukemia (CML)

By Treatment Type

Targeted drugs & immunotherapy

Chemotherapy

By Molecule Type

Small Molecules

Biologics

By Mode of Administration

Injectable

Oral

By Gender

Male

Female

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-east Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of the Middle East and Africa

Browse the full report at https://www.credenceresearch.com/report/leukemia-therapeutics-treatment-market

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: sales@credenceresearch.com